NBIX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.1B
+17.1%
959.0M
+17.7%
814.5M
+1.1%
805.5M
+1.3%
794.9M
Cost of Revenue
26.6M
+14.7%
23.2M
+68.1%
13.8M
-21.6%
17.6M
+35.4%
13.0M
Gross Profit
1.1B
+17.1%
935.8M
+16.9%
800.7M
+1.6%
787.9M
+0.8%
781.9M
Operating Expenses
764.8M
-2.5%
784.3M
+23.3%
635.9M
+10.2%
577.0M
+6.3%
542.9M
R&D
351.8M
+7.7%
326.7M
+10.3%
296.2M
+14.7%
258.2M
+3.3%
250.0M
SG&A
366.3M
-16.7%
439.7M
+38.1%
318.5M
+5.5%
301.8M
+3.5%
291.6M
Operating Income
331.3M
+118.7%
151.5M
-8.1%
164.8M
-21.9%
210.9M
-11.8%
239.0M
EBITDA
403.5M
+150.2%
161.3M
-16.6%
193.3M
-17.9%
235.4M
-5.5%
249.0M
Net Income
206.5M
+43.0%
144.4M
-27.0%
197.9M
+28.8%
153.7M
-26.6%
209.5M
EPS (Basic)
$2.03
+42.0%
$1.43
-27.4%
$1.97
+27.9%
$1.54
-27.0%
$2.11
EPS (Diluted)
$1.96
+41.0%
$1.39
-27.2%
$1.91
+29.1%
$1.48
-27.5%
$2.04
Shares (Diluted)
105.2M
+1.0%
104.2M
+0.8%
103.4M
-0.6%
104.0M
+1.5%
102.5M
Neurocrine Biosciences (NBIX) — Financials